Dr. Murat A. Anamur, MD

Dr. Anamur practices at Lowell General Hospital in Lowell, Massachusetts, part of Tufts Medicine.

Dr. Anamur's NPI, 1487601100, was assigned on May 28, 2006. Dr. Anamur holds Massachusetts license 72107.

Dr. Anamur's primary practice is Lowell General Hospital, at 295 Varnum Avenue, Lowell, MA 01854 in Middlesex County. The practice phone is (978) 937-6000.

Dr. Anamur's primary practice is Lowell General Hospital in Lowell, Massachusetts, part of Tufts Medicine. Dr. Anamur is also affiliated with Massachusetts General Hospital. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Anamur to 4 more hospitals, 2 medical groups and 1 physician office, each named with a free account. Dr. Anamur's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Anamur practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Anamur's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Anamur is licensed in Massachusetts.

CMS data shows 140 Medicare services from Dr. Anamur across 4 procedure codes in 2024, all of them office visits, for 138 Medicare patients. Medicare paid $11,732 for them.

CMS counts 138 Medicare patients who saw Dr. Anamur in 2024. The largest group is 75 to 84, with 69 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Anamur's median patient age at 73, with 47% women.

In 2024, Dr. Anamur wrote 59 Medicare Part D claims for 23 patients. 49% of them were for generic drugs. CMS names the drug for 38 of them, across 2 drugs with 11 or more claims each, at $9,553 in total drug cost. In 2023, CMS named 192 claims across 8 drugs.

Dr. Anamur accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Anamur to 10 clinical trials, 5 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung and Colorectal Neoplasms, Hereditary Nonpolyposis. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 45 general payments to Dr. Anamur from 18 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 80% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,613.